• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of sexual medicine >Is Testosterone Replacement Therapy in Males with Hypogonadism Cost-Effective? An Analysis in Sweden
【24h】

Is Testosterone Replacement Therapy in Males with Hypogonadism Cost-Effective? An Analysis in Sweden

机译：男性性腺功能减退症的睾丸激素替代疗法是否有效？瑞典的分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Testosterone replacement therapy (TRT) has been recommended for the treatment of primary and secondary hypogonadism. However, long-term implications of TRT have not been investigated extensively. Aim: The aim of this analysis was to evaluate health outcomes and costs associated with life-long TRT in patients suffering from Klinefelter syndrome and late-onset hypogonadism (LOH). Methods: A Markov model was developed to assess cost-effectiveness of testosterone undecanoate (TU) depot injection treatment compared with no treatment. Health outcomes and associated costs were modeled in monthly cycles per patient individually along a lifetime horizon. Modeled health outcomes included development of type 2 diabetes, depression, cardiovascular and cerebrovascular complications, and fractures. Analysis was performed for the Swedish health-care setting from health-care payer's and societal perspective. One-way sensitivity analyses evaluated the robustness of results. Main Outcome Measures: The main outcome measures were quality-adjusted life-years (QALYs) and total cost in TU depot injection treatment and no treatment cohorts. In addition, outcomes were also expressed as incremental cost per QALY gained for TU depot injection therapy compared with no treatment (incremental cost-effectiveness ratio [ICER]). Results: TU depot injection compared to no-treatment yielded a gain of 1.67 QALYs at an incremental cost of 28,176 EUR (37,192 USD) in the Klinefelter population. The ICER was 16,884 EUR (22,287 USD) per QALY gained. Outcomes in LOH population estimated benefits of TRT at 19,719 EUR (26,029 USD) per QALY gained. Results showed to be considerably robust when tested in sensitivity analyses. Variation of relative risk to develop type 2 diabetes had the highest impact on long-term outcomes in both patient groups. Conclusion: This analysis suggests that lifelong TU depot injection therapy of patients with hypogonadism is a cost-effective treatment in Sweden. Hence, it can support clinicians in decision making when considering appropriate treatment strategies for patients with testosterone deficiency.
机译：简介：睾丸激素替代疗法（TRT）已被推荐用于治疗原发性和继发性性腺功能低下。但是，TRT的长期影响尚未得到广泛研究。目的：本分析的目的是评估患有克莱因费尔特氏综合症和迟发性性腺功能低下（LOH）的患者的终生TRT相关的健康结果和费用。方法：建立了马尔可夫模型以评估十一酸睾丸激素（TU）贮库注射治疗与未治疗相比的成本效益。在每个人的一生中，以每个患者每月的周期来模拟健康结果和相关费用。建模的健康结果包括2型糖尿病，抑郁症，心脑血管并发症以及骨折的发生。从卫生保健付款人和社会的角度对瑞典的卫生保健环境进行了分析。单向敏感性分析评估了结果的稳健性。主要结局指标：主要结局指标是质量校正的生命年（QALYs）和TU储库注射治疗的总成本，无治疗队列。此外，结局还表示为TU储库注射疗法与未治疗相比每QALY获得的增量费用（增量成本效益比[ICER]）。结果：在Klinefelter人群中，与不进行处理相比，TU储库注射产生了1.67 QALY，增量成本为28,176 EUR（37,192 USD）。每个QALY获得的ICER为16,884欧元（22,287美元）。在LOH人群中，每获得QALY，TRT带来的收益估计为19,719欧元（26,029美元）。当在敏感性分析中进行测试时，结果显示出相当强的鲁棒性。在两个患者组中，发展为2型糖尿病的相对风险的变化对长期结局的影响最大。结论：该分析表明，在瑞典，性腺功能减退患者的终生TU库注射疗法是一种经济有效的疗法。因此，在考虑针对睾丸激素缺乏症患者的适当治疗策略时，它可以支持临床医生的决策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号